Diagnosis and management of infections associated with immunosuppression. New antibiotics of potential importance for immunosuppressed patients.
D000606:Amino Sugars / Q000627:therapeutic use; D001419:Bacteria / Q000201:enzymology; D002228:Carbenicillin / Q000627:therapeutic use*; D002506:Cephalexin / Q000627:therapeutic use; D002509:Cephaloridine / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy; D006027:Glycosides / Q000627:therapeutic use; D007116:Immunization, Passive; D007165:Immunosuppression Therapy; D007612:Kanamycin / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000138:chemical synthesis / Q000627:therapeutic use; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000276:immunology; D018805:Sepsis / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000606:Amino Sugars; D002511:Cephalosporins; D006027:Glycosides; D010406:Penicillins; D007612:Kanamycin; D002228:Carbenicillin; D002509:Cephaloridine; D002506:Cephalexin; D002512:Cephalothin